122769-75-9

Upstream product

• 37169-42-9 (S)-benzyl 2-(((benzyloxy)carbonyl)amino)-3-(3,4-dihydroxyphenyl)propanoate 
• 100-44-7 benzyl chloride 
• 59-92-7 levodopa 
• 501-53-1 benzyl chloroformate 
• 30033-25-1 (S)-2-(((benzyloxy)carbonyl)amino)-3-(3,4-dihydroxyphenyl)propanoic acid 
• 100-39-0 benzyl bromide 
• 21209-51-8 N-benzyloxycarbonyl-L-serine benzyl ester 
• 65926-39-8 (R)-benzyl 2-(((benzyloxy)carbonyl)amino)-3-iodopropanoate 
• 289471-92-7 2-(benzyloxy)-4-iodophenol 
• 6272-38-4 O-benzylcatechol 

Downstream Products

• 122769-77-1 L-N-benzyloxycarbonyl-3-(3-benzyloxy-4-pivaloyloxyphenyl)alanine benzyl ester 
• 122769-71-5 L-3-(3-hydroxy-4-pivaloyloxyphenyl)alanine hydrochloride 

Relevant academic research and scientific papers

Carbidopa and L-Dopa Prodrugs and Methods of Use

The present disclosure relates to (a) carbidopa prodrugs, (b) pharmaceutical combinations and compositions comprising a carbidopa prodrug and/or an L-dopa prodrug, and (c) methods of treating Parkinson's disease and associated conditions comprising admini

CARBIDOPA AND L-DOPA PRODRUGS AND THEIR USE TO TREAT PARKINSON'S DISEASE

The present disclosure relates to (a) carbidopa prodrugs, (b) pharmaceutical combinations and compositions comprising a carbidopa prodrug and/or an L-dopa prodrug, and (c) methods of treating Parkinson's disease and associated conditions comprising administering a carbidopa prodrug and an L-dopa prodrug to a subject with Parkinson's disease.

Hydrolysis and acyl migration of a catechol monoeter of L-dopa: L-3-(3-hydroxy-4-pivaloyloxyphenyl)alanine

Hydrolysis and acyl migration studies on L-3-(3-hydroxy-4-pivaloyloxyphenyl)alanine (1, NB-355), which produced long-lasting plasma L-dopa levels after oral dosing, have been conducted. Compound 1 exists as pure 4-O-pivaloyl-L-dopa in the solid state, but